Compare KSS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSS | IMNM |
|---|---|---|
| Founded | 1962 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 1992 | 2020 |
| Metric | KSS | IMNM |
|---|---|---|
| Price | $18.63 | $22.66 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 14 | 9 |
| Target Price | $16.08 | ★ $31.22 |
| AVG Volume (30 Days) | ★ 3.5M | 2.5M |
| Earning Date | 11-25-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | ★ $15,751,000,000.00 | $9,679,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.53 |
| P/E Ratio | $10.76 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.04 | $5.15 |
| 52 Week High | $25.22 | $25.30 |
| Indicator | KSS | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 38.77 | 60.67 |
| Support Level | $19.28 | $20.05 |
| Resistance Level | $20.67 | $22.01 |
| Average True Range (ATR) | 1.15 | 1.28 |
| MACD | -0.36 | 0.04 |
| Stochastic Oscillator | 3.55 | 82.00 |
Kohl's operates about 1,150 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also has a large digital sales operation. Women's apparel is Kohl's largest category, having generated 25% of its 2024 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.